These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 20193174)

  • 1. [Myocardial hypoperfusion due to microvascular dysfunction in hypertrophic cardiomyopathy: role of positron emission tomography].
    Cecchi F; Olivotto I; Baldi M; Maron MS; Maron BJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Dec; 37(12):1069-73. PubMed ID: 20193174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microvascular dysfunction, myocardial ischemia, and progression to heart failure in patients with hypertrophic cardiomyopathy.
    Cecchi F; Sgalambro A; Baldi M; Sotgia B; Antoniucci D; Camici PG; Sciagrà R; Olivotto I
    J Cardiovasc Transl Res; 2009 Dec; 2(4):452-61. PubMed ID: 20560003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Myocardial fibrosis progression on cardiac magnetic resonance in hypertrophic cardiomyopathy.
    Choi HM; Kim KH; Lee JM; Yoon YE; Lee SP; Park EA; Lee W; Kim YJ; Cho GY; Sohn DW; Kim HK
    Heart; 2015 Jun; 101(11):870-6. PubMed ID: 25897040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coronary microvascular dysfunction and ischemia in hypertrophic cardiomyopathy. Mechanisms and clinical consequences.
    Olivotto I; Cecchi F; Camici PG
    Ital Heart J; 2004 Aug; 5(8):572-80. PubMed ID: 15554027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional Stress-Induced Ischemia in Non-fibrotic Hypertrophied Myocardium in Young HCM Patients.
    Jablonowski R; Fernlund E; Aletras AH; Engblom H; Heiberg E; Liuba P; Arheden H; Carlsson M
    Pediatr Cardiol; 2015 Dec; 36(8):1662-9. PubMed ID: 26066352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coronary microvascular function, myocardial metabolism, and energetics in hypertrophic cardiomyopathy: insights from positron emission tomography.
    Timmer SA; Knaapen P
    Eur Heart J Cardiovasc Imaging; 2013 Feb; 14(2):95-101. PubMed ID: 23152441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of quantitative myocardial positron emission tomography for risk stratification in patients with hypertrophic cardiomyopathy: a 2016 reappraisal.
    Castagnoli H; Ferrantini C; Coppini R; Passeri A; Baldini K; Berti V; Cecchi F; Olivotto I; Sciagrà R
    Eur J Nucl Med Mol Imaging; 2016 Dec; 43(13):2413-2422. PubMed ID: 27527796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myofilament gene mutations.
    Olivotto I; Girolami F; Sciagrà R; Ackerman MJ; Sotgia B; Bos JM; Nistri S; Sgalambro A; Grifoni C; Torricelli F; Camici PG; Cecchi F
    J Am Coll Cardiol; 2011 Aug; 58(8):839-48. PubMed ID: 21835320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy: Current state of the art.
    Kamal MU; Riaz IB; Janardhanan R
    Cardiol J; 2016; 23(3):250-63. PubMed ID: 27064795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: comparison between cardiac MRI and PET.
    Knaapen P; van Dockum WG; Bondarenko O; Kok WE; Götte MJ; Boellaard R; Beek AM; Visser CA; van Rossum AC; Lammertsma AA; Visser FC
    J Nucl Med; 2005 Jun; 46(6):923-9. PubMed ID: 15937301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive evaluation of myocardial fibrosis in hypertrophic cardiomyopathy with cardiac magnetic resonance imaging: linking genotype with fibrotic phenotype.
    Ellims AH; Iles LM; Ling LH; Chong B; Macciocca I; Slavin GS; Hare JL; Kaye DM; Marasco SF; McLean CA; James PA; du Sart D; Taylor AJ
    Eur Heart J Cardiovasc Imaging; 2014 Oct; 15(10):1108-16. PubMed ID: 24819852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR.
    Moravsky G; Ofek E; Rakowski H; Butany J; Williams L; Ralph-Edwards A; Wintersperger BJ; Crean A
    JACC Cardiovasc Imaging; 2013 May; 6(5):587-96. PubMed ID: 23582356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The regional myocardial microvascular dysfunction differences in hypertrophic cardiomyopathy patients with or without left ventricular outflow tract obstruction: assessment with first-pass perfusion imaging using 3.0-T cardiac magnetic resonance.
    Xu HY; Yang ZG; Sun JY; Wen LY; Zhang G; Zhang S; Guo YK
    Eur J Radiol; 2014 Apr; 83(4):665-72. PubMed ID: 24521610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of myocardial fibrosis assessed with cardiac magnetic resonance in hypertrophic cardiomyopathy.
    Todiere G; Aquaro GD; Piaggi P; Formisano F; Barison A; Masci PG; Strata E; Bacigalupo L; Marzilli M; Pingitore A; Lombardi M
    J Am Coll Cardiol; 2012 Sep; 60(10):922-9. PubMed ID: 22935464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myocardial tissue characterization by gadolinium-enhanced cardiac magnetic resonance imaging for risk stratification of adverse events in hypertrophic cardiomyopathy.
    Raiker N; Vullaganti S; Collins JD; Allen BD; Choudhury L
    Int J Cardiovasc Imaging; 2020 Jun; 36(6):1147-1156. PubMed ID: 32166506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Young patients with hypertrophic cardiomyopathy, but not subjects at risk, show decreased myocardial perfusion reserve quantified with CMR.
    Gyllenhammar T; Fernlund E; Jablonowski R; Jögi J; Engblom H; Liuba P; Arheden H; Carlsson M
    Eur Heart J Cardiovasc Imaging; 2014 Dec; 15(12):1350-7. PubMed ID: 25139907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of late gadolinium enhancement in end-stage hypertrophic cardiomyopathy and dilated cardiomyopathy: differential diagnosis and prediction of cardiac outcome.
    Machii M; Satoh H; Shiraki K; Saotome M; Urushida T; Katoh H; Takehara Y; Sakahara H; Ohtani H; Wakabayashi Y; Ukigai H; Tawarahara K; Hayashi H
    Magn Reson Imaging; 2014 Feb; 32(2):118-24. PubMed ID: 24315973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hypertrophic non-obstructive cardiomyopathy assessed by dipyridamole thallium single photon emission computed tomography: comparisons with hypertrophic cardiomyopathy with a dilated heart].
    Mori T; Suda K; Ohnishi M; Kanoh Y; Shiotani H; Yokota Y; Fujitani K; Fukuzaki H; Maeda K
    J Cardiol; 1987 Mar; 17(1):35-46. PubMed ID: 3501444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron-emission tomography myocardial blood flow quantification in hypertrophic cardiomyopathy.
    Sciagrà R
    Q J Nucl Med Mol Imaging; 2016 Dec; 60(4):354-61. PubMed ID: 27611709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained arrhythmic events in hypertrophic cardiomyopathy.
    Prinz C; Schwarz M; Ilic I; Laser KT; Lehmann R; Prinz EM; Bitter T; Vogt J; van Buuren F; Bogunovic N; Horstkotte D; Faber L
    Can J Cardiol; 2013 Mar; 29(3):358-63. PubMed ID: 22749647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.